Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4732 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Naturewise Biotech & Medicals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Naturewise Biotech & Medicals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Naturewise Biotech & Medicals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Naturewise Biotech & Medicals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Naturewise Biotech & Medicals (ROCO:4732) has a Buyback Yield % of 3.09 as of Jul. 23, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Naturewise Biotech & Medicals and its competitors. This is 162% above median its historical median of 1.18. According to the industry distribution chart, Naturewise Biotech & Medicals ranks #16 out of 739 companies in the Biotechnology industry, placing it in the top 2.2%.
Is Naturewise Biotech & Medicals' Buyback Yield % too high?
Naturewise Biotech & Medicals' current Buyback Yield % of 3.09 is 162% above median its 10-year median of 1.18. Based on the distribution chart, Naturewise Biotech & Medicals ranks #16 out of 739 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Naturewise Biotech & Medicals has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Naturewise Biotech & Medicals' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Naturewise Biotech & Medicals ranks #16 out of 739 companies for Buyback Yield %. This places Naturewise Biotech & Medicals in the top 2% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Naturewise Biotech & Medicals and its competitors. Naturewise Biotech & Medicals's current Buyback Yield % is 3.09, which is 162% above median its own 10-year median of 1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Naturewise Biotech & Medicals stock overvalued right now?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals (ROCO:4732) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$22.06, compared to a current price of NT$16.55 — trading 25% below its estimated fair value. The current Buyback Yield % is 3.09, which is 162% above median its 10-year median of 1.18. Naturewise Biotech & Medicals' overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Naturewise Biotech & Medicals (ROCO:4732), the current Buyback Yield % is 3.09 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Naturewise Biotech & Medicals (ROCO:4732) Overvalued in 2026?
Based on GuruFocus' analysis, Naturewise Biotech & Medicals stock appears to be undervalued.
The current stock price of NT$16.55 is trading 25% below its estimated GF Value™ of NT$22.06.
GuruFocus considers Naturewise Biotech & Medicals to be Modestly Undervalued.
Key valuation signals for ROCO:4732:
Buyback Yield %: 3.09 (162% above median its 10-year median of 1.18)
GF Value™: NT$22.06 vs. price of NT$16.55 (25% below fair value)
No single metric tells the full story. See the ROCO:4732 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Naturewise Biotech & Medicals Business Description
Naturewise Biotech & Medicals Corp is a Taiwan-based drug development company that focuses on botanical drug and small molecule therapies. Its products include NBM-BMX Oral Softgel Capsule, Lipocol Forte Capsule, and PPLs Taiwan Green Propolis.
63GF Score
Get the complete analysis for ROCO:4732
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4732 has been successfully added to your 
